Immunosuppression involving soluble CD83 induces tolerogenic dendritic cells that prevent cardiac allograft rejection

Transplantation

Volumn 90, Issue 11, 2010, Pages 1145-1156

  Ge, Wei ^a   Arp, Jacqueline ^a   Lian, Dameng ^a   Liu, Weihua ^a   Baroja, Miren L ^a   Jiang, Jifu ^a   Ramcharran, Siobhan ^a   Eldeen, Firas Zahr ^a   Zinser, Elisabeth ^b   Steinkasserer, Alexander ^b   Chou, Perry ^c   Brand, Stephen ^d   Nicolette, Charles ^d   Garcia, Bertha ^a   Wang, Hao ^a,e  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^c UNIVERSITY OF WATERLOO   (Canada)

^d Argos Therapeutics Inc   (United States)

^e LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Adoptive transfer; Heart transplantation; Soluble CD83; Tolerance; Tolerogenic dendritic cells

Indexed keywords

CD45RB ANTIGEN; CD83 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; RAPAMYCIN;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; ARTICLE; CARDIAC GRAFT REJECTION; CELL FUNCTION; CELL MATURATION; CONTROLLED STUDY; CROSS TOLERANCE; DENDRITIC CELL; GRAFT RECIPIENT; GRAFT SURVIVAL; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SKIN GRAFT;

ADOPTIVE TRANSFER; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD11C; ANTIGENS, CD45; DENDRITIC CELLS; DRUG THERAPY, COMBINATION; GRAFT REJECTION; HEART TRANSPLANTATION; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNOGLOBULINS; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE AGENTS; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, INBRED C57BL; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; SIROLIMUS; SKIN TRANSPLANTATION; TIME FACTORS; TRANSPLANTATION TOLERANCE; TRANSPLANTATION, HOMOLOGOUS;

EID: 78650308229     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181f95718     Document Type: Article

References (70)

1. Wood KJ, Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol 2003; 3: 199.
2. Min WP, Zhou D, Ichim TE, et al. Inhibitory feedback loop between tolerogenic dendritic cells and regulatory T cells in transplant tolerance. J Immunol 2003; 170: 1304.
3. Morelli AE, Thomson AW. Tolerogenic dendritic cells and the quest for transplant tolerance. Nat Rev Immunol 2007; 7: 610.
4. Dilioglou S, Cruse JM, Lewis RE. Function of CD80 and CD86 on monocyte- and stem cell-derived dendritic cells. Exp Mol Pathol 2003; 75: 217.
5. Pardoll DM. Spinning molecular immunology into successful immu-notherapy. Nat Rev Immunol 2002; 2: 227.
6. Hock BD, Kato M, McKenzie JL, et al. A soluble form of CD83 is released from activated dendritic cells and B lymphocytes, and is detectable in normal human sera. Int Immunol 2001; 13: 959.
7. Zhou LJ, Tedder TF. Human blood dendritic cells selectively express CD83,amember ofthe immunoglobulin superfamily.J Immunol 1995; 154: 3821.
8. Zhou LJ, Schwarting R, Smith HM, et al. A novel cell-surface molecule expressed by human interdigitating reticulum cells, Langerhans cells, and activated lymphocytes is a new member of the Ig superfamily. J Immunol 1992; 149: 735.
9. Breloer M, Kretschmer B, Luthje K, et al. CD83 is a regulator of murine B cell function in vivo. Eur J Immunol 2007; 37: 634.
10. Kretschmer B, Luthje K, Schneider S, et al. Engagement of CD83 on B cells modulates B cell function in vivo. J Immunol 2009; 182: 2827.
11. + T cell longevity in vivo. J Immunol 2007; 179:4550.
12. Nicod LP, Joudrier S, Isler P, et al. Upregulation of CD40, CD80, CD83 or CD86 on alveolar macrophages after lung transplantation. J Heart Lung Transplant 2005; 24: 1067.
13. + NK helper cells. J Exp Med 2005; 202: 941.
14. Yamashiro S, Wang JM, Yang D, et al. Expression of CCR6 and CD83 by cytokine-activated human neutrophils. Blood 2000; 96: 3958.
15. Kruse M, Rosorius O, Kratzer F, et al. Mature dendritic cells infected with herpes simplex virus type 1 exhibit inhibited T-cell stimulatory capacity. J Virol 2000; 74: 7127.
16. Kummer M, Turza NM, Muhl-Zurbes P, et al. Herpes simplex virus type 1 induces CD83 degradation in mature dendritic cells with immediate-early kinetics via the cellular proteasome. J Virol 2007; 81:6326.
17. Lechmann M, Krooshoop DJ, Dudziak D, et al. The extracellular domain of CD83 inhibits dendritic cell-mediated T cell stimulation and binds to a ligand on dendritic cells. J Exp Med 2001; 194: 1813.
18. Lechmann M, Berchtold S, Hauber J, et al. CD83 on dendritic cells: More than just a marker for maturation. Trends Immunol 2002; 23:273.
19. Lechmann M, Kotzor N, Zinser E, et al. CD83 is a dimer: Comparative analysis of monomeric and dimeric isoforms. Biochem Biophys Res Commun 2005; 329: 132.
20. Scholler N, Hayden-Ledbetter M, Dahlin A, et al. Cutting edge: CD83 regulates the development of cellular immunity. J Immunol 2002; 168: 2599.
21. Dudziak D, NimmerjahnF, Bornkamm GW, et al. Alternative splicing generates putative soluble CD83 proteins that inhibit T cell proliferation. J Immunol 2005; 174: 6672.
22. Kotzor N, Lechmann M, Zinser E, et al. The soluble form of CD83 dramatically changes the cytoskeleton of dendritic cells. Immunobiology 2004; 209: 129.
23. Zinser E, Lechmann M, Golka A, et al. Prevention and treatment of experimental autoimmune encephalomyelitis by soluble CD83. J Exp Med 2004; 200: 345.
24. Xu JF, Huang BJ, Yin H, et al. A limited course of soluble CD83 delays acute cellular rejection of MHC-mismatched mouse skin allografts. Transpl Int 2007; 20: 266.
25. Lutz MB, Schuler G. Immature, semi-mature and fully mature dendritic cells: Which signals induce tolerance or immunity? Trends Im-munol2002; 23: 445.
26. + T cell-mediated suppression by dendritic cells. Science 2003; 299: 1033.
27. Lechmann M, Kremmer E, Sticht H, et al. Overexpression, purification, and biochemical characterization of the extracellular human CD83 domain and generation of monoclonal antibodies. Protein Expr Purif 2002; 24: 445.
28. Jen KY, Campo M, He H, et al. CD45RB ligation inhibits allergic pulmonary inflammation by inducing CTLA4 transcription. J Immunol 2007; 179: 4212.
29. Hackstein H, Thomson AW. Dendritic cells: Emerging pharmacological targets of immunosuppressive drugs. Nat Rev Immunol 2004; 4: 24.
30. + T regulatory cells and promote organ transplant tolerance. J Immunol 2007; 178: 7018.
31. Basadonna GP, Auersvald L, Khuong CQ, et al. Antibody-mediated targeting of CD45 isoforms: A novel immunotherapeutic strategy. Proc Natl Acad Sci USA 1998; 95: 3821.
32. Luke PP, O'Brien CA, Jevnikar AM, et al. Anti-CD45RB monoclonal antibody-mediated transplantation tolerance. Curr Mol Med 2001; 1: 533.
33. Zhong RZ, Lazarovits AI. Monoclonal antibody against CD45RB for the therapy of rejection and autoimmune diseases. JMol Med 1998; 76: 572.
34. Lazarovits AI, Poppema S, Zhang Z, et al. Prevention and reversal of renal allograft rejection by antibody against CD45RB. Nature 1996; 380: 717.
35. Zhang Z, Lazarovits A, Gao Z, et al. Prolongation of xenograft survival using monoclonal antibody CD45RB and cyclophosphamide in rat-to-mouse kidney and heart transplant models. Transplantation 2000; 69: 1137.
36. Gao Z, ZhongR, Jiang J, et al. Adoptively transferable tolerance induced by CD45RB monoclonal antibody. J Am Soc Nephrol 1999; 10: 374.
37. Sho M, Harada H, Rothstein DM, et al. CD45RB-targeting strategies for promoting long-term allograft survival and preventing chronic allograft vasculopathy. Transplantation 2003; 75: 1142.
38. Wang H, Hosiawa KA, Min W, et al. Cytokines regulate the pattern of rejection and susceptibility to cyclosporine therapy in different mouse recipient strains after cardiac allografting. J Immunol 2003; 171: 3823.
39. Arp J, LeVatte M, Rowe J, et al. A source of glycosylated human T-cell lymphotropic virus type 1 envelope protein: Expression of gp46 by the vaccinia virus/T7 polymerase system. J Virol 1996; 70: 7349.
40. Arp J, Ford CM, Palker TJ, et al. Expression and immunogenicity of the entire human T cell leukaemia virus type I envelope protein produced in abaculovirus system. J Gen Virol 1993; 74(pt 2): 211.
41. Devasahayam M. Factors affecting the expression of recombinant glycoproteins. Indian J Med Res 2007; 126: 22.
42. Werner RG, Kopp K, Schlueter M. Glycosylation of therapeutic proteins in different production systems. Acta Paediatr Suppl 2007; 96: 17.
43. Nickerson P, Steurer W, Steiger J, et al. Cytokines and the Th1/Th2 paradigm in transplantation. Curr Opin Immunol 1994; 6: 757.
44. Janeway C. Immunobiology: The immune system in health and disease [ed. 6]. New York; London, Garland Science 2005.
45. Cramer SO, Trumpfheller C, Mehlhoop U, et al. Activation-induced expression of murine CD83 on T cells and identification of a specific CD83 ligand on murine B cells. Int Immunol 2000; 12: 1347.
46. Breloer M, Fleischer B. CD83 regulates lymphocyte maturation, activation and homeostasis. Trends Immunol 2008; 29: 186.
47. Gavin MA, Rasmussen JP, Fontenot JD, et al. Foxp3-dependent programme of regulatory T-cell differentiation. Nature 2007; 445: 771.
48. Fontenot JD, Rasmussen JP, Williams LM, et al. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 2005; 22: 329.
49. + T cell tolerance in vivo. Immunity 2008; 28: 521.
50. Lechler R, Ng WF, Steinman RM. Dendritic cells in transplantation- Friend or foe? Immunity 2001; 14: 357.
51. Desai DD, Harbers SO, Flores M, et al. Fc gamma receptor IIB on dendritic cells enforces peripheral tolerance by inhibiting effector T cell responses. J Immunol 2007; 178: 6217.
52. Game DS, Lechler RI. Pathways of allorecognition: Implications for transplantation tolerance. Transpl Immunol 2002; 10: 101.
53. Mahnke K, Schmitt E, Bonifaz L, et al. Immature, but not inactive: The tolerogenic function of immature dendritic cells. Immunol Cell Biol 2002; 80: 477.
54. Lopez-Bravo M, Ardavin C. In vivo induction of immune responses to pathogens by conventional dendritic cells. Immunity 2008; 29: 343.
55. Jonuleit H, Schmitt E, Schuler G, et al. Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. JExp Med 2000; 192: 1213.
56. + T cells. JIm-munother 2005; 28: 560.
57. Oluwole OO, Depaz HA, Gopinathan R, et al. Indirect allorecogni-tion in acquired thymic tolerance: Induction of donor-specific permanent acceptance of rat islets by adoptive transfer of allopep-tide-pulsed host myeloid and thymic dendritic cells. Diabetes 2001; 50: 1546.
58. Taner T, Hackstein H, Wang Z, et al. Rapamycin-treated, alloantigen-pulsed host dendritic cells induce ag-specific T cell regulation and prolong graft survival. Am J Transplant 2005; 5: 228.
59. Baban B, Hansen AM, Chandler PR, et al. A minor population of splenic dendritic cells expressing CD19 mediates IDO-dependent T cell suppression via type IIFN signaling following B7 ligation. Int Immunol 2005; 17: 909.
60. Mellor AL, Chandler P, Baban B, et al. Specific subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA4-mediated induction of indoleamine 2,3 dioxygenase. Int Immunol 2004; 16: 1391.
61. Ochando JC, Homma C, Yang Y, et al. Alloantigen-presenting plasma-cytoid dendritic cells mediate tolerance to vascularized grafts. NatIm-munol2006; 7: 652.
62. Olfert ED, Cross BM, McWilliam AA. Responsibility for the care and use of experimental animals. In: Olfert ED, Cross BM, McWilliam AA, eds. Guide to the care and use of experimental animals, vol. 1. Ottawa, Association of Universities and Colleges of Canada 1993, pp 1.
63. Corry RJ, Winn HJ, Russell PS. Primarily vascularized allografts of hearts in mice. The role of H-2D, H-2K, and non-H-2 antigens in rejection. Transplantation 1973; 16: 343.
64. Wang H, Arp J, Liu W, et al. Inhibition of terminal complement components in presensitized transplant recipients prevents antibody-mediated rejection leading to long-term graft survival and accommodation. JImmu-nol2007; 179: 4451.
65. Wang H, Arp J, Huang X, et al. Distinct subsets of dendritic cells regulate the pattern of acute xenograft rejection and susceptibility to cyclosporine therapy. J Immunol 2006; 176: 3525.
66. Racusen LC, Halloran PF, Solez K. Banff 2003 meeting report: New diagnostic insights and standards. Am J Transplant 2004; 4: 1562.
67. Binder J, Lehmann M, Graser E, et al. The effects of nondepleting CD4 targeted therapy in presensitized rat recipients of cardiac allografts. Transplantation 1996; 61: 804.
68. Onodera K, Lehmann M, Akalin E, et al. Induction of " infectious" tolerance to MHC-incompatible cardiac allografts in CD4 monoclonal antibody-treated sensitized rat recipients. J Immunol 1996; 157: 1944.
69. Ge W, Jiang J, Baroja ML, et al. Infusion of mesenchymal stem cells and rapamycin synergize to attenuate alloimmune responses and promote cardiac allograft tolerance. Am J Transplant 2009; 9: 1760.
70. Wadia PP, Herrera ND, Abecassis MM, et al. Mycophenolic acid inhibits maturation and function of human dendritic cells and B cells. Hum Immunol2009; 70: 692.